BPC-157: A Reconstitution Walkthrough

BPC-157 is the compound people most often reconstitute first, and the one most often described with more confidence than the evidence supports. This article does two separate things, in this order: the arithmetic, which is settled, and the evidence, which is not.

The two vial sizes you'll meet

BPC-157 is typically supplied as 5 mg or 10 mg of lyophilised powder. Both are handled identically — only the concentration differs. VialPal does not supply the dose: enter the dose and concentration from your clinician, pharmacy, product instructions, or research protocol. VialPal handles the math.

What the water volume does

Concentration is the milligrams in the vial divided by the millilitres of bacteriostatic water added. On a U-100 insulin syringe, where 100 units make 1 mL, that fixes how many micrograms each unit mark carries:

To turn that into a draw, divide the dose from your instructions, in micrograms, by the mcg per unit for your vial. The result is the number of units to read on the barrel.

Note rows two and four: identical concentration, identical mcg per unit, but one vial holds twice the peptide of the other. The milligrams in the vial set how much there is to draw from; the water sets how large each draw is. They are independent, and confusing them is the origin of most bad advice on this topic. Run your own numbers in the calculator.

A more concentrated solution packs more micrograms into each unit, so a small dose lands on only a few units — close to the resolution floor of the syringe. If you find yourself squinting at the barrel, that is the signal to use more water on the next vial rather than to try harder.

Storage specifics

Per the library entry: the lyophilised powder is refrigerated; stable at room temperature for short periods. Reconstituted, refrigerate at 2–8°c. commonly cited as usable for ~30 days.

BPC-157's human half-life is not characterised. The only published pharmacokinetic study is preclinical, in rats and dogs, and there is no human pharmacokinetic data to reason from. What you can track is the solution itself: log the date each vial was reconstituted and check it against the window above, because potency lost after that point is invisible — the storage guide covers why.

What the evidence actually shows

BPC-157 has a substantial preclinical literature — a large fraction of it from a single research group, led by Predrag Sikiric, over roughly three decades. Across rat and mouse models it has been reported to accelerate healing in tendon, ligament, muscle, bone, and gastrointestinal tissue, and to show effects on angiogenesis and on nitric-oxide pathways.

The limitations are as important as the findings:

• Almost entirely animal work. The healing results people cite are from rodents. Effects in rodent tendon do not reliably transfer to human tendon, and the history of regenerative medicine is largely a history of that gap.
• Very little human data. There have been early-phase safety studies, but there is no adequately powered randomised controlled trial demonstrating an efficacy outcome in humans for any injury indication. “No published RCT” is not the same as “doesn't work” — it means the question is open.
• Concentrated provenance. When most of a literature originates with one group, independent replication carries disproportionate weight, and there is comparatively little of it.
• Unknown long-term safety. Short-term tolerability in animals appears good, and no consistent toxicity signal has emerged. That is a much weaker statement than an established human safety profile. The angiogenic mechanism in particular has not been characterised for long-term human use.
• Oral bioavailability is unsettled. It is often described as orally active, which for a 15-amino-acid peptide facing gastric proteases is a strong claim. The supporting data is largely from the same preclinical body of work.

What to record

Whatever instructions you are working from, the log is what makes them interpretable later. Record the dose in micrograms, the concentration, the unit count, the injection site, and the reconstitution date of the vial it came from. A log reading “5 units” is meaningless once the next vial is mixed differently; the same entry with the microgram amount, “at 5 mg/mL” and “vial opened 12 Jun” still means something in six weeks, including whether it came from a vial past its window.

Half-life, vial sizes and storage for the other compounds in the library are listed the same way, with regulatory status stated on every one.